Kazazian Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Kazazian Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18,794	Closed	-$334K	–	103
2018 Q3	$334K	Sell	18,794 -6,264	-25%	-$108K	0.31%	59
2018 Q2	$346K	Sell	25,058 -7,465	-23%	-$88.6K	0.32%	63
2018 Q1	$296K	Buy	+32,523	New	+$179K	0.31%	64

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Kazazian Asset Management's ECYT Position: Q4 2018 in Review

Kazazian Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 18,794 shares — an estimated $334K sold.

Kazazian Asset Management first reported a position in ECYT in Q1 2018 and held it in 3 quarters. The position peaked at $346K in Q2 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Kazazian Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Kazazian Asset Management sold 18,794 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $334K.
Kazazian Asset Management first reported a position in Endocyte, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
Kazazian Asset Management's Endocyte, Inc. Common Stock position peaked at $346K in Q2 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.